Trials / Completed
CompletedNCT00330083
Safety of ALK Ragweed Tablet
A RANDOMIZED, MULTIPLE DOSE, DOSE-ESCALATION, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE I TRIAL INVESTIGATING THE OPTIMAL SAFE DOSE OF ALK RAGWEED TABLET AMBROSIA ARTEMISIIFOLIA IN ADULT SUBJECTS WITH SEASONAL RHINOCONJUNCTIVITIS CAUSED BY RAGWEED POLLEN ALLERGY
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 72 (estimated)
- Sponsor
- ALK-Abelló A/S · Industry
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Not accepted
Summary
This trial is performed to assess whether ALK Ragweed Tablet is safe to use in adults
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | ALK Ragweed Tablet |
Timeline
- Start date
- 2006-05-01
- First posted
- 2006-05-25
- Last updated
- 2007-09-21
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00330083. Inclusion in this directory is not an endorsement.